Evidence map›Paper›PMID 36495480›Full record

ArticleBJU international2023

Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?

Matthew Trail, Muhammad Sajid Waheed Rahman, William J Broadhurst, James P Blackmur, Abhishek Sharma, Etienne Chew, Marie O'Donnell, Julian Y Keanie, John Brush, John Taylor and 7 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in BJU international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Matthew TrailDepartment of Urology, Western General Hospital, Edinburgh, UK.ORCID 0000-0003-0131-8064
Muhammad Sajid Waheed RahmanCollege of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.
William J BroadhurstCollege of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.
James P BlackmurDepartment of Urology, Western General Hospital, Edinburgh, UK.ORCID 0000-0001-7267-837X
Abhishek SharmaDepartment of Urology, Western General Hospital, Edinburgh, UK.
Etienne ChewCollege of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.
Marie O'DonnellDepartment of Histopathology, Western General Hospital, Edinburgh, UK.
Julian Y KeanieDepartment of Radiology, Western General Hospital, Edinburgh, UK.
John BrushDepartment of Radiology, Western General Hospital, Edinburgh, UK.
John TaylorDepartment of Radiology, Western General Hospital, Edinburgh, UK.
Simon PhippsDepartment of Urology, Western General Hospital, Edinburgh, UK.
Ben ThomasDepartment of Urology, Western General Hospital, Edinburgh, UK.
Edward A A MainsDepartment of Urology, Western General Hospital, Edinburgh, UK.ORCID 0000-0002-9766-3032
S Alan McNeillDepartment of Urology, Western General Hospital, Edinburgh, UK.
Steve LeungDepartment of Urology, Western General Hospital, Edinburgh, UK.
Mark L CutressDepartment of Urology, Western General Hospital, Edinburgh, UK.
Alexander LairdDepartment of Urology, Western General Hospital, Edinburgh, UK.ORCID 0000-0002-7296-025X
Western General Hospital · GBEdinburgh College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify clinicopathological or radiological factors that may predict a diagnosis of upper urinary tract urothelial cell carcinoma (UTUC) to inform which patients can proceed directly to radical nephroureterectomy (RNU) without the delay for diagnostic ureteroscopy (URS). PATIENTS AND

methodsAll consecutive patients investigated for suspected UTUC in a high-volume UK centre between 2011 and 2017 were identified through retrospective analysis of surgical logbooks and a prospectively maintained pathology database. Details on clinical presentation, radiological findings, and URS/RNU histopathology results were evaluated. Multivariate regression analysis was performed to evaluate predictors of a final diagnosis of UTUC.

resultsIn all, 260 patients were investigated, of whom 230 (89.2%) underwent URS. RNU was performed in 131 patients (50.4%), of whom 25 (9.6%) proceeded directly without URS - all of whom had a final histopathological diagnosis of UTUC - and 15 (11.5%) underwent RNU after URS despite no conclusive histopathological confirmation of UTUC. Major surgery was avoided in 77 patients (33.5%) where a benign or alternative diagnosis was made on URS, and 14 patients (6.1%) underwent nephron-sparing surgery. Overall, 178 patients (68.5%) had a final diagnosis of UTUC confirmed on URS/RNU histopathology. On multivariate logistic regression analysis, a presenting complaint of visible haematuria (hazard ratio [HR] 5.17, confidence interval [CI] 1.91-14.0; P = 0.001), a solid lesion reported on imaging (HR 37.8, CI = 11.7-122.1; P < 0.001) and a history of smoking (HR 3.07, CI 1.35-6.97; P = 0.007), were predictive of a final diagnosis of UTUC. From this cohort, 51 (96.2%) of 53 smokers who presented with visible haematuria and who had a solid lesion on computed tomography urogram had UTUC on final histopathology.

conclusionWe identified specific factors which may assist clinicians in selecting which patients may reliably proceed to RNU without the delay of diagnostic URS. These findings may inform a prospective multicentre analysis including additional variables such as urinary cytology.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsUreteral NeoplasmsUrinary Bladder NeoplasmsHematuriaHumansProspective StudiesRetrospective StudiesUreteroscopyCT urographydiagnosisdiagnostic ureteroscopypathwayupper urinary tract urothelial cell carcinoma#uroonc#utucUTUCUUTUC

Identifiers

PMID36495480
OpenAlexW4311024095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.